## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Joachim BRENDEL et al.

Examiner:

R. Desai

Art Unit:

1625

Application No.: 10/691,624

Title: 2'-SUBSTITUTED 1, 1'-BIPHENYL-2-

Filed: **October 24, 2003** 

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND

PHARMACEUTICAL PREPARATIONS

CARBOXAMIDES, PROCESSES FOR

COMPRISING THEM

August 9, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

RECEIVED **CENTRAL FAX CENTER** 

AUG 0 @ 2005

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

$\boxtimes$	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	•	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
	$\boxtimes$	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			1

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The reference, Pharmakologie und Toxikologie, describes the class III antiarrhythmics Amiodaron and Sotalol, which are K+-channel blockers. The reference describes the chemical structures of Amiodaron and Sotalol, the mode of action, the application, the pharmacokinetic and the side effects.

Respectfully submitted,

Joseph D. Rossi, Reg. No. 47,038

Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. DEAV1999/L060 US NP2

authorized.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Joachim BRENDEL et al.

Application No.: 10/691,624

Filed: October 24, 2003

Title: 2'-SUBSTITUTED 1, 1'-BIPHENYL-2-CARBOXAMIDES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Examiner:

R. Desai

Art Unit:

1625

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit August 9, 2005

Printed Name of Person Signing Certificate Paul Irvine

Signature

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 RECEIVED CENTRAL FAX CENTER

AUG 0 4 2005

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

oseph D. Rossi, Reg. No. 47,038

Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. DEAV1999/L060 US NP2

	_		•		PTC/SB/08A (10-98) Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE espend to a collection of information unless it contains a valid OMB control number.			
Si	ubstitute	for form 1449A/PTC	,		Complete if Known			
					Application Number	10/691,624		
	type a plus sign (+) inside this box  the Paperwork Reduction Act of 1995, no persona are require Substitute for form 1449A/PTO  INFORMATION DISCLOSURI STATEMENT BY APPLICAN  (use as many sheets as necessary)  Sheet 1 of 2	SCLOSURE	Filing Date	10-24-2003				
9	TAT	EMENT B	Y	\PPLICANT	First Named Inventor	BRENDEL		
					Group Art Unit	1625		
	(	use as many she	ets a	s necessary)	Examiner Name	DESAI, Rita J.		
Sh	eet	1	of	2	Attorney Docket Number	DEAV1999/L060 - US - NP - 2		

				U.S. PATENT DOCI	JMENTS	•
Examiner Initials	Cite No.1	U.S. Pater Number	Kind Code <sup>2</sup> (If Impwn)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					1	
						,
				•		
			11			
		•		-		
			1 1			
					·	
						····
-						

				FORE	IGN PATENT DOCUMEN	<b>1</b> 5				
Examiner	030	Cite	Oile	F	oreign Patent Do		Name of Patentee or	Date of Publication of	Pagas, Columns, Linas, Where Relevant	
inidals"	No.1	Office <sup>3</sup>	Number <sup>4</sup>	lGnd Coda⁵ (lf known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T₽		
								1_		
						-		┼		
		<del>  </del>				<del> </del>		╁╴		
						<u> </u>	•	+		
						<del> </del>		+		

Examiner	Date
Signature	Considered
V1911414114	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

	Please type a plus sign (+) inside this box -> TO/SB/08B (10-96)  Approved for use through 10/31/99, DMB 0651-0031  Patent and Traderteark Office: U.S. DEPARTMENT OF COMMERCE  Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlass it contains a valid DMB control number.									
Substitute for form 1449B/PTO					Complete if Known					
- 1					Application Number	10/691,624				
ŀ	INF	ORMATIO	N D	ISCLOSURE	Filing Date	10-24-2003				
-	STA	TEMENT	RY	APPLICANT	First Named Inventor	BRENDEL				
- 1	917	7 : FIG: FIG :		/ ( · C.O/ (11)	Group Art Unit	1625				
- 1		(use as many	sheet	s as necessary)	Examiner Name	DESAI, Rita J.				
Į	Sheet	2	of	2	Attorney Docket Number	DEAV1999/L060 - US - NP - 2				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
eleiliner nilisis	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-assue number(s), publisher, city and/or country where published.	T²
		BRANDMEIER, et al., Antiparallel beta-Sheet Conformation in Gyclopeptides Containing a Pseudo-amino Acid with a Biphenyl Moiety, Helvetica Chima Acta; 77; 1994; pp. 70-85.	
		LULLMAN, et al., Pharmakologie und Toxikologie; XP002159084, Georg Thleme Verlag, Stuttgart; 1999; pp.151-153.	-
		Caplus AN 2001:608248 English Abstract, Chemstar Product List RN# 326284 May 16, 2001	
<b>^</b>			
<del>- •:</del>			
	<del> </del>		
			,
Examine	r	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not classical is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.